Search the Newsreel

Kura Oncology, Inc. $KURA Shares Sold by Renaissance Technologies LLC

Kura Oncology Inc (KURA) Financial Health: Profitability & Balance Sheet Analysis

Kura Oncology Inc (KURA) has a current financial score of 6.02, indicating a weak financial status and low operating efficiency within the Biotechnology & Medical Research industry. Despite this, the company reported a year-over-year revenue increase of 29.47% and a net profit increase of …

Kura Oncology Inc (KURA) Earnings Forecast: Future EPS & Revenue Growth Estimates

This article provides an earnings forecast for Kura Oncology Inc (KURA), highlighting its current earnings forecast score, analyst ratings, and price targets. The company ranks 146 out of 384 in the Biotechnology & Medical Research industry, with most analysts recommending a "Buy" for the …

Kura Oncology (KURA) to Announce Quarterly Earnings on Thursday

Kura Oncology Reports Durable Clinical Activity of Darlifarnib Plus Cabozantinib in Cabozantinib-Naïve Clear Cell Renal Cell Carcinoma Patients at KCRS 2026

Kura Oncology announced encouraging and durable clinical activity results from its FIT-001 clinical trial for darlifarnib plus cabozantinib in cabozantinib-naïve clear cell renal cell carcinoma patients. The study showed objective response rates up to 50% and a median progression-free survival of 13 months, with …

Kura Oncology (NASDAQ: KURA) revises CEO and executive severance

Kura Oncology (NASDAQ: KURA) has revised the employment agreements for its CEO, CCO, and COO to update severance and change-of-control protections. These new terms define cash severance, COBRA coverage, equity vesting, and stock option exercise rights, differentiating based on whether a termination is linked …

A Quick Look at Today's Ratings for Kura Oncology(KURA.US), With a Forecast Between $28 to $40

This article provides a quick look at analyst ratings for Kura Oncology (KURA.US). Forecasts for the company's stock price range from $28 to $40. Investors are encouraged to consider these ratings as part of a broader investment strategy.

KURA Reiterates by Wedbush -- Price Target Maintained at $36

Wedbush has reiterated an "Outperform" rating for Kura Oncology (KURA) and maintained a price target of $36.00, signaling confidence despite the company's low GF Score™ of 28/100, which highlights profitability and growth challenges. Insider activity, marked by $1.0 million in net selling and no …

Kura Oncology Reports 50% Response Rate in RCC Combination Study

Kura Oncology announced promising updated results from its Phase 1 FIT-001 trial, showing a 50% objective response rate in cabozantinib-naive clear cell RCC patients treated with darlifarnib and cabozantinib. The combination therapy demonstrated a manageable safety profile, with neutropenia being the most notable adverse …

H.C. Wainwright Maintains Kura Oncology(KURA.US) With Buy Rating, Maintains Target Price $40

H.C. Wainwright has reiterated its Buy rating for Kura Oncology (KURA.US), maintaining a target price of $40. This suggests a continued positive outlook on the company's stock performance.

Kura Oncology Reports Encouraging Phase 1a Data for Darlifarnib Plus Cabozantinib in Advanced Clear Cell Renal Cell Carcinoma

Kura Oncology announced positive Phase 1a results from its FIT-001 clinical trial for darlifarnib plus cabozantinib in patients with advanced clear cell renal cell carcinoma (ccRCC). The combination therapy demonstrated response rates up to 50% and a median progression-free survival of 13 months, along …

Kura Oncology reports up to 50% response rate for darlifarnib-cabozantinib combo in Phase 1a kidney cancer trial

Kura Oncology announced positive Phase 1a results for its darlifarnib-cabozantinib combination therapy in advanced clear cell renal cell carcinoma, showing up to a 50% response rate and durable tumor shrinkage. The company is currently enrolling for a randomized Phase 1b study to determine the …

Kura Sushi USA, Inc. Revenue Breakdown – NASDAQ:KRUS

Why Did KURA Stock Jump 13% In Pre-Market Today?

Kura Oncology (KURA) shares surged over 13% in pre-market trading after the biotech firm reported encouraging early data from its ongoing trial for advanced kidney cancer. The trial for its investigational therapy, Darlifarnib, in combination with Cabozantinib, showed a 44% objective response rate and …

Kura Oncology Inc (KURA) Valuation: PE, PB & Fair Value Analysis

This article provides a valuation analysis of Kura Oncology Inc (KURA), stating its current valuation score is 6.69, ranking 304 out of 386 in the Biotechnology & Medical Research industry. It details the company's current P/E ratio, noting its fluctuation compared to recent highs …

Kura Oncology Inc (KURA) Institutional Confidence

Kura Oncology Inc (KURA) shows a high institutional confidence score of 10.00, placing it 1st within the Biotechnology & Medical Research industry. Institutional ownership stands at 103.35%, indicating a quarterly increase of 4.16%. While James Simons is listed as the largest shareholder by percentage, …

Enterprise value to EBIT forward of Kura Oncology, Inc. – NASDAQ:KURA

This article focuses on the enterprise value to EBIT forward of Kura Oncology, Inc. (NASDAQ: KURA). It appears to be a financial data page from TradingView, providing an overview of the company's financials without offering detailed analysis or news. The content primarily lists standard …

KURA|Kura Oncology Inc|Price:10.390|Chg%:-0.060

Kura Oncology Inc. (KURA) is a clinical-stage biopharmaceutical company focused on cancer treatment, with its stock currently trading at $10.39. Analysts have given it a "Buy" rating with a target price of $31.17, indicating significant upside potential. Despite strong institutional ownership and high profit …

(KURA) and the Role of Price-Sensitive Allocations

Quantitative Research Desk published an analysis of Kura Oncology Inc. (NASDAQ: KURA), highlighting a mid-channel oscillation pattern and a strong 62.7:1 risk-reward setup targeting an 18.5% gain. The report details three institutional trading strategies (Long, Momentum Breakout, Risk Hedging) and a multi-timeframe signal analysis, …

Kura Sushi USA: Traffic Declines And Inflation Pressures (Rating Downgrade)

Barclays Maintains Kura Oncology(KURA.US) With Buy Rating, Maintains Target Price $28

Barclays has reiterated its Buy rating on Kura Oncology (KURA.US) and maintained its target price of $28. This reflects the firm's continued positive outlook on the company's stock performance.

Kura Sushi USA (NASDAQ: KRUS) insider files to sell 3,024 Class A shares

An insider at Kura Sushi USA (NASDAQ: KRUS) has filed to sell 3,024 Class A shares, valued at approximately $134,487.74, on or around July 20, 2026, via NASDAQ. The shares are held at Fidelity Brokerage Services LLC and originate from restricted stock awards that …

Kura Sushi USA, Inc. (NASDAQ:KRUS) Given Average Rating of "Hold" by Analysts

Enterprise value to EBITDA forward of Kura Oncology, Inc. – NASDAQ:KURA

The article focuses on the enterprise value to EBITDA forward for Kura Oncology, Inc. (NASDAQ: KURA). It presents financial data for the company obtained from various market data providers shown within the TradingView platform.

Analysts Are Upgrading Fujikura Ltd. (TSE:5803) After Its Latest Results

Fujikura (TSE:5803) Stock Faces Rich Valuation As EPS Growth Reinforces Bullish Narratives

[Nikkei 8-Day Rally & AI Stocks Surge] Fujikura Revises Guidance Upward and $10.5 Trillion Physical AI Investment Drive Markets; Kioxia's Market Cap Hits $60 Trillion

Fujikura (TSE:5803) Stock Looks Pricey After Surprise Guidance Upgrade

Fujikura Shares Jump 16% After Profit Forecast Raised to 310 Billion

Fujikura Shares Surge 16% as Outlook Hike Calms Market Jitters

Tokyo market opens higher: Nikkei average extends gains for seventh straight day. Fujikura shows strong buying interest, boosted by its upward earnings revision, lifting wire and optical device-related stocks. Kioxia surpasses the ¥100,000 mark. Space-relate

Earnings call transcript: Kura Oncology Q1 2026 revenue miss overshadows stable EPS

Some Analysts Just Cut Their Kura Oncology, Inc. (NASDAQ:KURA) Estimates

Analysts Have Lowered Expectations For Kura Oncology, Inc. (NASDAQ:KURA) After Its Latest Results

Earnings Update: Kura Oncology, Inc. (NASDAQ:KURA) Just Reported And Analysts Are Trimming Their Forecasts

Kura Oncology, Inc. Q1 2026 Earnings Call Summary